BioTime, Inc. (BTX) Submits Clinical Investigation Protocol
BioTime recently announced that the company has submitted Clinical Investigation Protocol (CIP) to European authorities in order to begin studies for its Renevia stem cell delivery platform. Based in Alameda, CA, BioTime is focused on regenerative medicine and blood plasma volume expanders. Its broad platform of stem cell technologies is enhanced through subsidiaries focused on specific fields of application. BioTime also develops and markets products for the stem cell and regenerative medicine industries, including its PureStem cell lines, HyStem hydrogels, culture media, and differentiation kits. The Principal Investigator for the studies will be Ramon Llull, MD, and the planned trials…